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Abstract
Introduction: A number of genetic-association studies have identified genes contributing to ankylosing spondylitis
(AS) susceptibility but such approaches provide little information as to the gene activity changes occurring during
the disease process. Transcriptional profiling generates a ‘snapshot’ of the sampled cells’ activity and thus can
provide insights into the molecular processes driving the disease process. We undertook a whole-genome
microarray approach to identify candidate genes associated with AS and validated these gene-expression changes
in a larger sample cohort.
Methods: A total of 18 active AS patients, classified according to the New York criteria, and 18 gender- and age-
matched controls were profiled using Illumina HT-12 whole-genome expression BeadChips which carry cDNAs for
48,000 genes and transcripts. Class comparison analysis identified a number of differentially expressed candidate genes.
These candidate genes were then validated in a larger cohort using qPCR-based TaqMan low density arrays (TLDAs).
Results: A total of 239 probes corresponding to 221 genes were identified as being significantly different between
patients and controls with a P-value <0.0005 (80% confidence level of false discovery rate). Forty-seven genes were
then selected for validation studies, using the TLDAs. Thirteen of these genes were validated in the second patient
cohort with 12 downregulated 1.3- to 2-fold and only 1 upregulated (1.6-fold). Among a number of identified
genes with well-documented inflammatory roles we also validated genes that might be of great interest to the
understanding of AS progression such as SPOCK2 (osteonectin) and EP300, which modulate cartilage and bone
metabolism.
Conclusions: We have validated a gene expression signature for AS from whole blood and identified strong
candidate genes that may play roles in both the inflammatory and joint destruction aspects of the disease.
Introduction
Ankylosing spondylitis (AS) is a chronic inflammatory
rheumatic disease characterised by inflammation that
leads to bone resorption and bone formation, ultimately
resulting in progressive ankylosis [1]. Although the
aetiopathogenesis of AS is not yet clearly defined, both
susceptibility to and severity of this disease are highly
heritable. The major gene association is with the MHC I
gene HLA-B27 with 95% of patients positive for this
gene [2-4]. However, only approximately 5% of HLA-
B27 carriers suffer from AS, meaning other genes are
involved in disease susceptibility. In fact, twin and family
studies have suggested that HLA-B27 accounts for less
than 40% of the overall risk for AS [2,4]. In recent years
genetic-association studies have identified several new
genes in association with AS. Some of these genes
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associations [5,6]. Nevertheless, the mechanism by
which HLA-B27 and other more recently identified
genetic factors involved in AS susceptibility, lead to dis-
ease remains uncertain.
Genetic studies provide little information as to the
gene activity changes occurring during the disease pro-
cess. Gene-expression profiling confers a “snapshot” of
cellular activity providing information on mechanisms
mediating disease changes, elucidating possible pathways
involved and can also generate diagnostic gene sets. In
AS and spondyloarthritis (SpA) a number of recent stu-
dies have defined transcriptional profiles generated from
peripheral blood mononuclear cells (PBMCs) isolation
requiring immediate sample processing, which is not
suitable for larger multicentre studies and limits the via-
bility of such an approach [7]. An alternate approach is
to use whole blood samples collected using PAXgene
technology which preserves the integrity of the RNA
even with limited storage at room temperature allowing
delays in transport and handling to occur with minimal
RNA degradation [7].
In the current study, we undertook a whole-genome
microarray approach to identify a genomic profiling in a
Portuguese case-control collection, using RNA from
peripheral blood collected using the PAXgene collection
system, and validated these gene-expression changes in
an independent larger sample cohort using quantitative
PCR (qPCR). Our goal was to test whether genomic
profiling in such cases, using the more practical PAX-
gene Blood RNA System
®, could distinguish AS cases
from healthy controls, and identify genomic pathways
likely to be involved in AS pathogenesis.
Materials and methods
Study subjects
The microarray-based discovery study was performed
using samples from 18 AS patients, diagnosed according
to the modified New York criteria [8], and 18 gender-
and age-matched healthy controls (±5 years). Included
patients had Bath Ankylosing Spondylitis Disease Activ-
ity Index (BASDAI) scores >4 and Bath Ankylosing
Spondylitis Functional Index (BASFI) scores >4. All
patients were receiving only NSAIDs and/or sulphasala-
zine. No TNF, corticoid or methotrexate treated patients
were included. Details of the study subjects are shown
in Supplementary Table S1 in Additional file 1.
Candidate genes were validated in a second larger
cohort of another 78 AS patients and 78 age and sex
matched controls (full details in Supplementary Table
S2 in Additional file 2).
Peripheral blood samples were collected into PAXgene
Blood RNA System
® tubes (Qiagen, Doncaster, VIC,
Australia) and stored according to the manufacturer’s
recommendations [9]. This study was approved by the
Ethics Committees of the participating centres, and writ-
ten informed consent was obtained from the individuals
involved in this study.
RNA processing and array analysis
Total RNA was extracted from whole blood samples
according to the standard PAXgene protocol, quantified
and the integrity assessed by Agilent 2100 BioAnalyser
(Agilent, Santa Clara, CA, USA). Only samples with a
RNA integrity number above 7.5 were used. To mini-
mize the effects of Globin RNA transcript over-repre-
sentation, samples were processed with Ambion
GLOBINclear
® (Applied Biosystems, Mulgrave, VIC,
Australia) according to the manufacturer’sp r o t o c o l .
cRNA was generated from 500 ng of total RNA using
the Illumina TotalPrep cRNA Amplification Kit
® (ABI)
and hybridized to Human HT-12 V3 Expression Bead-
Chips (Illumina, San Diego, CA, USA). Array data were
processed using the Illumina GenomeStudio software,
transformed by variance stabilization transformation
(VST) [10] and normalized by robust spline normaliza-
tion [11] using Lumi [12]. Quality control using princi-
pal components analysis showed four samples to be
outliers and further investigation revealed technical
issues with the processing of these samples and thus
they were excluded from the analysis.
Gene expression analysis was performed in BRB-
ArrayTools [13]. Differentially expressed genes were
identified by unpaired t-test with multivariate permuta-
tion correction. Gene ontology analysis was carried out
in BRB ArrayTools using a LS permutation test which
finds gene sets that have more genes differentially
expressed among the classes than it would be expected
by chance using 100,000 random geneset permutations
to compare to the chosen geneset.
Candidate gene validation using quantitative reverse
transcription polymerase chain reaction
Candidate genes were identified from the array studies
based upon their fold-change between AS and control,
the P-value of this difference and their potential biologi-
cal relevance to AS. Candidate genes were assayed using
real-time quantitative PCR-based (qPCR) predesigned
TaqMan Low Density Array Cards (TLDA). The TLDA
cards had 48 predesigned Taqman qPCR assays, which
utilise MGB probes with FAM dye, arrayed in a 384-
well format allowing four samples to be assayed per
TLDA. Forty-seven candidate genes selected from the
whole genome arrays together with a housekeeping gene
(18s) were arrayed. cDNA was generated from 1 μgo f
total RNA using the Bioline cDNA synthesis Kit
(Bioline, London, UK) according to manufacturer’s
instructions. qPCR was carried out using SensiMix dT
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under the following conditions; 50°C for 2 minutes,
95°C for 10 minutes, and 40 cycles of 95°C for 15 s and
60°C for 60 s [14].
Data were normalized using the housekeeping gene,
18S, included on the card and quantified using the
2
-ΔCT [ 1 5 ] .D a t aw e r ea n a l y s e dw i t ht h eM a n n - W h i t n e y
test and P-values <0.05 were considered significant
(SPSS v17.0, Chicago, IL, USA).
Results
Differential gene expression in AS patients and controls
From a total of more than 48,000 probes on the array,
18,159 were found to be expressed in at least one sample
and were included for analysis. To estimate the degree of
gene expression variation driven by disease status, we
undertook unsupervised hierarchical clustering using the
top 3% most variably expressed genes without reference
to disease status. Clustering with this non-biased geneset
gave good delineation between the controls and AS
patients with only six controls and five AS patients mis-
classifying (Figure 1). To identify the genes specifically
differentially expressed between patients and controls, we
carried out an unpaired T-test corrected for multiple
comparisons. A total of 648 probes were considered sig-
nificantly differentially expressed (80% confidence level
of false discovery rate, with 10% false positives) with 204
of these probes (corresponding to 190 genes) having
P-values <0.0005 (Supplementary Table S3 in Additional
file 3). The magnitude of differential expression observed
was generally low, with only three genes showing a signif-
icant fold-change >2 (with the maximum fold-change
being 2.21) and 29 genes >1.5 fold-change. Of the 204
probes, 89 probes were upregulated and 115 downregu-
lated. Our microarray data are available in a public repo-
sitory, Gene Expression Omnibus (GEO), with the
accession number [GEO:GSE25101].
We then selected 47 of the differentially expressed
genes for validation by qPCR (Table 1) based upon their
P-value, fold-change and biological relevance.
Quantitative RTPCR validation
Expression levels of the 47 selected genes were con-
firmed by qPCR in a second sample set consisting of 78
patients and 78 age and gender matched controls. A
total of 28 of the 47 genes showed a similar trend in dif-
ferential expression between AS and control samples as
the array data. Of these, 14 of the 47 considered genes
were validated with significant P-values with 13 downre-
gulated 1.4 to 2.2-fold and only 1 upregulated (1.6-fold)
(Table 2).
Gene ontology analysis
Gene ontology (GO) analysis on the dataset showed two
key immune-associated pathways to be altered, “negative
regulation of adaptive immune response” and several
ontologies affecting “thymic T cell selection” both with
P-values <0.005 (Table 3).
Discussion
Gene expression profiling in disease reveals the underly-
ing gene activity changes contributing to the disease
process. This information provides insight into the tis-
sue changes during the disease development and enables
targets for therapeutic intervention to be identified. Sec-
ondly, strong, consistent gene expression changes can
be utilized to generate diagnostic algorithms to identify
early-stage disease before significant tissue damage has
occurred.
However, in SpA, and in AS in particular, only a small
number of case-control genomic profiling studies have
been undertaken. The early studies involved low sample
numbers and poor genome coverage and were very het-
erogeneous in terms of methodology, including the
source of mRNA studied [16-19]. More recently four
studies using genome-wide microarrays showed interest-
ing results regarding SpA physiopathology and biomar-
ker identification [20-23]. Of these, two were PBMC
based [20,21] and in two the RNA was isolated from
unfractionated peripheral blood [22,23]. However, all
these studies did confirm that AS/SpA cases could be
reliably distinguished from healthy controls using geno-
mic profiling [20-23].
Although PBMCs have been widely used in autoim-
mune disease gene expression profiling studies, PBMCs
do not represent an ideal tissue source for larger scale
multicentre studies requiring extensive downstream pro-
cessing soon after collection. PAXgene tubes enable
whole blood to be collected directly into an RNA-pre-
servative which stabilises the RNA from degradation for
up to three days at room temperature, long enough for
Figure 1 Clustering on top 3% most variable genes.
Unsupervised hierarchical clustering based upon the top 3% most
variable genes (585 genes) showed good delineation between the
patient and control samples with six controls and five AS samples
misclassifying. The non-perfect classification suggests non-disease
related factors also drive the gene expression patterns.
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ever, differences in the transcriptional profile between
PBMC and PAXgene derived RNA have been demon-
s t r a t e d .T h e s ed i f f e r e n c e sa r ed u et ot h ed i f f e r e n tc e l l
populations targeted as well as the extra processing
steps required for PAXgene samples to prevent globin
mRNA overrepresentation affecting microarray sensitiv-
ity [9,24]. The study reported here has a number of
strengths in that it represents a multicenter study invol-
ving ethnically homogeneous patients with AS (defined
according to the modified New York criteria) and
excluded patients on anti-TNF agents. Use of a primary
dataset for candidate gene identification (by microar-
rays) followed by validation by qPCR in an independent
dataset provides additional robustness.
Using the most variably expressed genes for unsuper-
vised clustering gave us an estimate of the proportion of
the gene expression variation driven by disease status.
That only six controls and five AS samples were mis-
classified indicates the major driver of gene expression
as disease status. However, the fact that not all samples
classified correctly also indicates other factors driving
gene expression variation. Such factors may be differ-
ences in blood collection, storage and transport proto-
cols that can arise in multicentre studies. However,
none of these effects were robust enough to cluster
independently when tested (data not shown).
We validated 14 differentially expressed genes between
AS patients and healthy controls. A number of these
genes have well-documented inflammatory roles or an
action on bone/cartilage metabolism. Moreover, GO
analysis showed two key immune-associated pathways to
be altered, “negative regulation of adaptive immune
Table 1 Selected genes for validation by qPCR
Gene symbol Fold-change (AS/Cont) Parametric P-value
CX3CR1 0.58 3.45E-04
DGKQ 0.62 1.45E-05
SPOCK2 0.65 3.07E-04
SBK1 0.66 1.69E-04
GZMM 0.67 3.39E-04
CDC25B 0.67 2.00E-04
CLSTN1 0.68 4.53E-04
ITGB7 0.68 5.63E-04
PTPN1 0.69 1.50E-06
EP300 0.70 1.26E-04
DOCK10 0.70 1.73E-04
MAPK8IP3 0.70 3.37E-04
BCL11B 0.70 5.88E-04
DNMT1 0.71 6.46E-05
XPC 0.71 5.10E-06
PPP2R1A 0.71 1.73E-04
IL27RA 0.72 4.40E-06
MCM3 0.73 4.24E-04
SYF2 1.34 5.94E-04
PPP2R3C 1.36 1.07E-03
NGFRAP1 1.37 1.87E-04
ZMAT2 1.38 1.58E-04
MYL6 1.41 7.94E-05
S100A8 1.43 6.09E-04
GMFG 1.43 3.91E-05
VAMP5 1.44 4.21E-04
CKLF 1.46 4.30E-04
SHFM1 1.47 8.62E-04
ATG3 1.49 6.10E-04
MRPS18C 1.49 5.71E-04
CLEC4D 1.52 3.47E-04
UBL5 1.52 8.93E-05
AIF1 1.52 5.19E-04
PDCD10 1.54 2.45E-03
NDUFS4 1.54 5.93E-04
SF3B14 1.54 2.39E-04
HMGB2 1.57 3.41E-04
UQCRB 1.63 2.33E-04
TXN 1.68 4.39E-05
CMTM2 1.74 4.78E-04
CIP29 1.75 1.38E-04
CHMP5 1.78 6.80E-04
PSMA4 1.80 8.45E-05
NDUFB3 1.88 1.25E-04
LSM3 1.99 6.72E-04
GNG11 2.15 1.41E-04
CCDC72 2.21 9.64E-05
Genes (n = 47) for validation by qPCR were selected from the 648 probes
significantly differentially expressed in microarrays based upon their P-value,
fold-change and biological relevance. AS, Ankylosing spondylitis; qPCR,
quantitative polymerase chain reaction.
Table 2 Validated genes by qRTPCR
Parametric P-value Fold-change Gene symbol
2.90E-06 0.4457398 BCL11B
1.30E-06 0.4597414 DNMT1
2.50E-06 0.5009603 CDC25B
1.94E-05 0.5214546 CLSTN1
0.008539 0.5323253 VAMP5
1.81E-05 0.5435122 DOCK10
0.0005221 0.5693345 SPOCK2
0.0012085 0.5831974 ITGB7
0.001398 0.6124764 MCM3
0.0206755 0.6632639 CX3CR1
0.0026443 0.6749132 PTPN1
0.0034889 0.6847808 EP300
0.0125026 0.7141221 PPP2R1A
0.0184087 1.6090812 CLEC4D
Of the 47 considered genes, 14 were validated with significant P-values (P
<0.05). q-RTPCR, quantitative reverse transcription polymerase chain reaction.
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selection”. Interestingly the GO analysis indicated a
“negative” regulation of the immune system. This agrees
with a previous expression profiling recently reported in
P B M C sf r o mA Sp a t i e n t s[ 2 0 ]a n di sa l s oc o n s i s t e n t
with the “reverse IFN gamma signature” reported by
another group studying macrophages from AS patients
[19].
A possible reduced immune response also correlates
with the downregulation of PTPN1 and DOCK10, which
are both involved in mediating IL4 actions [25]. Protein
tyrosine phosphatase 1B (PTP1B) is a ubiquitously
expressed enzyme shown to negatively regulate multiple
tyrosine phosphorylation-dependent signalling pathways,
including IL4 signalling [26]. Dock10 is also regulated
by IL4 in B cells [27]. This is of particular interest as
I L 4m a yp l a yar o l ei nA Sp a t h o g e n e s i s .I n t e r l e u k i n4
(IL4), a 20-kDa product from activated T lymphocytes,
has a variety of stimulatory and inhibitory actions on B
and T cells [25,28-30]. Recent studies have also indi-
cated a potential role for IL4 producing CD8+ T cells in
the pathogenesis of AS. Although CD8+ T cells are pre-
dominately associated with the production of ‘Th1’ cyto-
kines, such as IFNgamma, there is now good evidence
that some subsets of these cells can also produce ‘Th2’
cytokines such as IL4, IL5 and IL10 [31]. The potential
functions associated with IL4-producing CD8+ T cells
are as yet unclear but the subtype CD8+/TCR alpha
beta + T cells, with a regulatory phenotype and function
(expressing CD25+, CTLA4+, Foxp3+, but negative for
IFNgamma and perforin), were previously described in
peripheral blood of AS patients [32]. These results were
confirmed in a recent study suggesting an altered pat-
tern of CD8+ T cell differentiation in AS and in HLA-
B27+ healthy individuals [33]. This predisposition to
generate IL4+CD8+ T cells may play a role in pathogen-
esis of SpA [32,33].
In addition, the activation of the innate immune sys-
tem has been proposed to play an important role in AS
inflammation. Dysregulation of Toll-like receptor (TLR)-
related pathways (an upregulation of TLR4 and TLR5),
involved in innate immune response, have been
described [23]. Interestingly we also identified increased
expression of TLRs 4 and 5, together with TLR1 but the
significance was marginal and, therefore, not followed
up. However, an upregulation of C-type lectin domain
family 4, member D (CLEC4D), another gene involved
in the innate immune response, was seen. CLEC4D has
been found to be expressed in a monocyte/macrophage
restricted manner, and although no ligand or biological
function has as yet been described, the receptor has
been shown to be upregulated at the transcript level in
a number of disease settings, similarly to two others
members of the family, Mincle and Dectin-2. They are
able to recognize and promote pathogen clearance and
induce inflammatory signals [34]. This process seems to
follow the Syk and caspase recruitment domain protein
(CARD9) pathway which was recently implicated in a
mouse model of SpA [35].
Changes in SPOCK2 (osteonectin) and EP300 provide
interesting insights into AS progression. SPOCK2,a l s o
known as Sparc/osteonectin, was implicated, in a recent
study, as a discriminator between SpA and healthy con-
trols [22] and has been hypothesised to play roles in the
regulation and production, assembly, or maintenance of
matrix turnover in cartilage [36,37]. In this process
TGFbeta and IFNgamma exert antagonistic effects, and
play important roles in the physiologic regulation of
extracellular matrix turnover. TGFbeta positively regu-
lates COL1A2 through the cellular Smad signal trans-
duction pathway, contrary to IFNgamma which
downregulates COL1A2 through Stat1. Interestingly, the
protein produced by EP300 belongs to the group of
nuclear p300/CBP transcriptional coactivators for both
Smad3 and Stat1a, and integrates signals that positively
or negatively regulate COL1A2 transcription [38]. In
addition, the downregulation of EP300 may promote a
pro-inflammatory status [39] contributing to cartilage
degradation. The protein phosphatase 2, regulatory sub-
unit A (PPP2R1A) has also been shown to play a role in
TGFb-mediated regulation of Smad3-activated genes
[40]. Finally, transactivated p300, controlled by phos-
phoinositide-3 kinase (PI3K)/AKT, is an important tran-
scriptional co-activator of Sox9 [41], which modulates
the expression of the major extracellular matrix compo-
nent, aggrecan. Not surprisingly, altered EP300 expres-
sion has been associated with the Wnt pathway, a key
mediator of bone formation as well as cartilage
Table 3 Gene ontology analysis
GO category GO ontology GO term LS permutation P-value
GO:0002820 BP Negative regulation of adaptive immune response 0.00001
GO:0033077 BP T cell differentiation in the thymus 0.00001
GO:0043383 BP Negative T cell selection 0.00001
GO:0045061 BP Thymic T cell selection 0.00001
The dataset showed two key immune-associated pathways to be altered, “negative regulation of adaptive immune response” and several ontologies affecting
“thymic T cell selection” both with P-values <0.005.
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these genes might lead to a loss of matrix integrity
thereby accelerating tissue damage. PTP1B has also
been shown to induce apoptosis in chondrocytes, thus
downregulation might result in increased chondrocyte
numbers contributing to joint damage as has been seen
in osteoarthritis [43]. Both EP300 and DNA (cytosine-5-
)-methyltransferase 1(DNMT1), mediate STAT3 func-
tionality [44] which has also been associated in genetic
studies with AS [45]. Decreases in STAT3 signalling
might also contribute to the hypothesised reduction in
immune response [46].
CX3CR1, which plays a pro-inflammatory role in RA,
was also downregulated. In RA, CX3CR1, and its ligand
CX3CL1, drives chemotaxis of pro-inflammatory mono-
cytes to inflammatory sites [47]. Decreased expression
of this gene in AS may reflect the fundamental differ-
ences in disease processes between AS and RA.
B e t a7i n t e g r i n sh a v eb e e ns h o w nt op l a yar o l ei n
chronic ileitis [48,49] a common clinical feature of SPA.
In our study, beta 7 integrin (ITGB7) is under-expressed
again possibly reflecting a decreased immune response
in AS.
The specific function of several other genes, as
BCL11B, CDC25B, VAMP5, MCM3, CLSTN1 have not
yet been determined and their potential involvement in
disease processes needs additional research.
Conclusions
We have validated a gene expression signature for AS
from whole blood and identified strong candidate genes
that may play roles in both the inflammatory environ-
ment and bone and cartilage effects. Future studies are
needed to confirm some of the possible interactions
suggested by this study.
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Additional file 1: Supplementary Table S1: Characteristics of
subjects involved in microarrays study. BASDAI, Bath Ankylosing
Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis
Functional Index; BASMI, Bath Ankylosing Spondylitis Metrology Index;
mSASSS, modified Stoke Ankylosing Spondylitis Spinal Score.
Additional file 2: Supplementary Table S2: Characteristics of
subjects involved in TLDA study.A S( n = 78) and healthy controls (n =
78). No significant differences for age and sex between groups.
Additional file 3: Supplementary Table S3: Genes differentially
expressed between AS patients and controls by microarrays. A total
of 648 probes were considered significantly differentially expressed (80%
confidence level of false discovery rate with 10% false positives).
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Activity Index; BASFI: Bath Ankylosing Spondylitis Functional Index; BASMI:
Bath Ankylosing Spondylitis Metrology Index; GO: gene ontology; mSASSS:
modified Stoke Ankylosing Spondylitis Spinal Score; PBMCs: peripheral blood
mononuclear cells; qPCR: quantitative polymerase chain reaction; q-RTPCR:
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